Multispan and Promega to Streamline GPCR Drug Screening Programs
News Jan 09, 2008
Multispan and Promega have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening. The companies will combine Multispan GPCR cell lines and Promega bioluminescent technologies to create optimized GPCR screening protocols.
The first tools will support cell lines and cAMP-Glo™ Assay for quantification of signal. Additional tools will be developed for cell-based assay detection.
This combination of validated biologic components with the most sensitive and dynamic luminescence assay detection technology for high-throughput screening will provide increased speed and efficiency in GPCR drug screening, both companies believe.
“Pre-optimized protocols will reduce assay development times, from months to days, helping deliver better GPCR targeted drugs faster,” according to John Watson, Marketing Director of Pharma/Biotech at Promega.
“Our suite of assay tools can be combined with Multispan’s validated GPCR cell lines to provide turnkey solutions for drug discovery scientists. Bioluminescent tools developed at Promega are routinely used to profile small molecule compounds, study druggable targets such as GPCRs, nuclear hormone receptors, proteases and kinases, and assess cell viability and cytotoxicity,” he added.
“Partnering with Promega further broadens the application of Multispan’s strong GPCR cell biology expertise. The combined offering from the two companies will benefit our customers enormously in drug discovery,” said Dr. Helena Mancebo, President & CEO of Multispan.